Cytek Biosciences (CTKB) Gross Margin (2020 - 2026)

Cytek Biosciences has reported Gross Margin for 7 years, with the latest figure at 48.16% in Q1 2026.

• For the quarter ending Q1 2026, Gross Margin fell 46.0% year-over-year to 48.16%; the trailing twelve-month figure through Mar 2026 stood at 51.7% (down 324.0% YoY), and the FY2025 full-year result was 51.84%, down 358.0% from the prior year.
• Gross Margin for Q1 2026 stood at 48.16%, down from 52.92% in the prior quarter.
• The five-year high for Gross Margin was 66.36% in Q3 2022, with the low at 48.16% in Q1 2026.
• Historically, Gross Margin has averaged 55.77% across 5 years, with a median of 56.62% in 2023.
• Annual changes were most pronounced in 2022 — Gross Margin soared 8798 bps — and 2023, when it plunged 974 bps.
• Cytek Biosciences' Gross Margin stood at 60.77% in 2022, then retreated by 7 bps to 56.75% in 2023, then grew by 3 bps to 58.55% in 2024, then fell by 10 bps to 52.92% in 2025, then decreased by 9 bps to 48.16% in 2026.
• The last three Gross Margin figures came in at 48.16% (Q1 2026), 52.92% (Q4 2025), and 52.69% (Q3 2025), per Business Quant data.